Latest News — Page 16

What if HTA decisions could be tracked in real time? 🔍📊

Infarmed’s new real-time Health Technology Assessment tracker brings greater transparency to appraisal timelines, evidence and outcomes. It gives manufacturers, payers and policymakers the data needed to anticipate market access, streamline submissions and improve planning.

Read the full article to see how the tracker works and what it means for regulatory strategy and market access.

#SyenzaNews #HealthTechnology #regulatoryaffairs #MarketAccess #DigitalTransformation

Is Merck’s Q1 2026 momentum all about oncology and cardiometabolic growth?

Merck posted a strong Q1 driven by its oncology and cardiometabolic portfolios, with pipeline advances and strategic investments supporting commercial momentum and investor confidence. The results underline how therapeutic leadership and targeted R&D are shaping near-term performance and guidance.

Read the full analysis for the key numbers, growth drivers, and what this means for the pharma landscape. 📈

#SyenzaNews #oncology #pharmaceuticals #innovation #MarketAccess

Ready to rethink the future of high-risk cancer treatments? 🧬🚀

ASCO 2026 showcased how adaptive trial designs, enhanced safety monitoring, and cross-sector collaboration can help responsibly scale novel oncology interventions—balancing accelerated access with patient safety and equitable implementation.

Read the full piece for practical takeaways for clinicians, regulators, and industry leaders driving the next wave of cancer care.

#SyenzaNews #oncology #clinicaltrials #innovation #MarketAccess

Can Europe rebuild public trust in vaccines? 🔍

The EMA has formed an advisory group that recommends clearer, more transparent risk communication, targeted engagement with healthcare professionals and patient groups, and proactive misinformation monitoring to shore up vaccine confidence. Their strategy calls for coordinated, data-driven action across regulators, industry and public health bodies to protect uptake and health outcomes.

Read the full article to see the group’s recommendations and what they mean for regulators, industry and practitioners. 💬

#SyenzaNews #regulatoryaffairs #globalhealth #healthcarepolicy #innovation

Concerned about recurring shortages of off‑patent medicines in Europe? 🛡️💊

This article examines how Europe can build supply‑chain resilience—covering local manufacturing, supplier diversification, strategic stockpiles, procurement reform, and regulatory incentives to reduce single‑source risk and protect patient access.

Read the full piece to discover practical policy and industry steps for securing medicine supplies.

#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

Could subcutaneous diuretic therapy keep heart failure patients out of hospital? 💡

Emerging subcutaneous delivery approaches enable effective outpatient diuresis, with early data showing fewer admissions, greater patient comfort, and new care-model opportunities for clinicians and MedTech companies.

Read the full article to explore the clinical evidence, implementation challenges, and implications for payers and device innovators.

#SyenzaNews #medicaldevices #MedTech #innovation #MarketAccess

Can TikTok signals help forecast opioid overdoses before they surge? 🔍📈

This piece highlights how combining TikTok trends with machine learning can provide early-warning signals for opioid overdose trends—boosting situational awareness for public health teams while surfacing privacy and bias challenges.

Read the full article to explore the predictive methods, real-world findings, and what this means for policymakers and healthcare responders.

#SyenzaNews #AIinHealthcare #digitalhealth #datascience #ai

Can the EMA’s new pilot accelerate access to breakthrough medical devices? 🚀

The pilot seeks to streamline early regulatory engagement, coordinated assessments and real‑world evidence pathways to help innovators bring high‑impact devices to patients faster while maintaining safety and effectiveness. It’s a potential game-changer for developers, payers and health systems navigating market access in Europe.

Read the full article for a practical breakdown of what the pilot means and how to prepare next steps.
#SyenzaNews #medicaldevices #regulatoryaffairs #MarketAccess #healthcarepolicy

Are systemic barriers stifling South Africa’s medical device innovation? 🩺

This article unpacks how regulatory complexity, funding shortfalls, fragmented procurement and skills gaps are slowing MedTech growth—and outlines practical solutions like streamlined approvals, targeted R&D funding, public‑private partnerships and support for local manufacturing to improve market access and scale homegrown solutions.

Read the full analysis on SyenzaNews to see the policy and industry actions that could unlock South Africa’s MedTech potential.

#SyenzaNews #medicaldevices #HealthcareInnovation #MarketAccess #innovation

Could wider access to a generic hormonal IUD transform contraceptive choice in South Africa? 💊

This article explores how Avibela’s generic entry could shift affordability, supply chains, and provider adoption — while outlining the regulatory and market-access barriers that must be addressed to scale up use.

Read the full analysis for practical implications and next steps for policymakers, manufacturers, and health systems.

#SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy

Is regulatory fragmentation across Europe delaying patient access to promising PSMA‑targeted therapies?

The article outlines how divergent national assessments, inconsistent evidence requirements, and staggered pricing/reimbursement decisions are creating a patchwork of access across EU Member States 🧬⚖️. It also presents practical solutions — from aligned evidence generation and joint HTA approaches to value‑based agreements — to speed equitable access.

Read the full piece to understand the barriers and pragmatic policy fixes that could unlock timely access across Europe.

#SyenzaNews #oncology #regulatoryaffairs #MarketAccess #healthcarepolicy

Could a pill change the game for teens with type 2 diabetes?

Early data from a pioneering study of oral semaglutide suggest it may improve glycemic control in adolescents while offering a non‑injectable alternative—potentially reshaping pediatric diabetes care and access. The article breaks down the clinical findings, safety considerations, and regulatory implications clinicians and policymakers should watch.

Read the full analysis to see what this could mean for practice and policy. 💊

#SyenzaNews #pharmaceuticals #clinicaltrials #innovation #healthcarepolicy

Could terminal complement inhibition be the next breakthrough for IgA nephropathy? 🔬

The I‑CAN trial explores targeting the terminal complement pathway in IgAN, showing promising signals that could reduce disease progression and reshape treatment options while raising important questions for regulators and payors.

Read the full analysis for clinical takeaways, regulatory implications, and what this means for patients and industry. 💡

#SyenzaNews #clinicaltrials #drugdevelopment #MarketAccess #innovation

Which predicts AKI better: a multicenter collaborative model or a locally trained model?

The study finds multicenter models deliver better generalizability and lower site-to-site bias, while local models can outperform at a single site unless properly recalibrated — highlighting the value of data harmonization, continuous validation, and federated approaches.
Read the full article for comparative results and practical steps to deploy robust AKI prediction in your setting. 🔬📈

#SyenzaNews #AIinHealthcare #HealthTech #datascience #ai

What does the CHMP’s April 2026 guidance mean for the future of rare-disease therapies? 🔍⚖️

The CHMP is sharpening the economic lens on orphan and ultra-orphan medicines—highlighting the need for stronger real-world evidence, clearer value frameworks, and flexible payment models to secure reimbursement and sustainable market access. This analysis breaks down the implications for developers, payers, and policymakers and outlines practical steps to de-risk launches.

Read the full breakdown to prepare your strategy.

#SyenzaNews #HealthEconomics #regulatoryaffairs #MarketAccess #costeffectiveness

Is European access to medicines at a critical crossroads because of US pricing pressures?

Rising US list prices and shifting pricing strategies are forcing European payers to rethink reference pricing, HTA approaches, and managed-entry agreements. This article outlines the policy choices and trade-offs that will shape affordability, innovation incentives, and timely patient access.

Read the full analysis to see what policymakers, payers, and industry can do next. 🔍

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy